Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6852W HIGH $2.39
Volume
1.47 K
Value Traded
25.58 K
Short % Float
3.56%
+1.83%Week
-36.93%1 Month
-9.76%3 Month
+39.97%6 Month
-80.12%5 Year
-89.19%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
8.96 M
EPS (TTM)
-0.48
P/E Ratio
-
Ent. Value
781.27 K
Total Shares
8.07 M
Float Shares
3.25 M
Insiders
-
Institutions
0.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
IMRN Catalyst Timeline
Dated clinical, regulatory and corporate events for Immuron Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for Immuron Limited
669Total events
11Upcoming
131Tier-1 (high impact)
2016 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicensePROIBS®Corporate
Executed exclusive distribution agreement for PROIBS® in the United States with Calmino group AB
abdominal pain, bloating and unsettled bowel movementssource ↗
▲Product LaunchPROIBS®Post-Market
Launch of PROIBS® in the United States
abdominal pain, bloating and unsettled bowel movementssource ↗
▲IND ClearanceIMM-529IND
FDA approval for IMM-529 IND application
Clostridioides difficile infectionsource ↗
▲Partnership / LicenseIMM-529Corporate
Engaged Pullan Consulting to advance IMM-529 partnering strategy
Clostridioides difficile infectionsource ↗
▲Partnership / LicenseIMM-529Corporate
Engaged Pullan Consulting to support partnering IMM-529
Clostridioides difficile infectionsource ↗
▲Product LaunchPROIBS®Post-Market
Launched PROIBS® in Australia during FY26
abdominal pain, bloating and unsettled bowel movementssource ↗
▲Product LaunchPROIBS®Post-Market
Launched PROIBS® in Australia during FY26
abdominal pain, bloating and unsettled bowel movementssource ↗
●Oral PresentationPresentation
CEO Steven Lydeamore presentation at Emerging Growth Conference
▲Quarterly UpdateCorporate
Immuron reported global product revenue of AUD $1.5 million for 3Q FY2026, 16% YoY growth
▲IND ClearanceIMM-529IND
FDA clearance to proceed into Phase 2 clinical trials for IMM-529
Clostridioides difficile infectionssource ↗
▲Quarterly UpdateTravelanCorporate
Q3 FY2026 sales AUD$1.5 million, up 16% on prior comparative period
travelers' diarrheasource ↗
▲Quarterly UpdateCorporate
Canada Q3 sales AUD$0.1M up >100% on pcp and up 82% on prior quarter
▲Product LaunchTravelanPost-Market
Travelan launch into Jean Coutu pharmacies in 3QFY26
traveler's diarrheasource ↗
●Oral PresentationPresentation
CEO Steven Lydeamore presenting at Coffee Microcaps Conference
▲Partnership / LicenseCorporate
Strategic decision to partner clinical assets IMM-124E and IMM-529
▲Product LaunchTravelanPost-Market
Travelan launch into Jean Coutu pharmacies in 3QFY26
Traveler's Diarrheasource ↗
●Trial InitiationIMM-529Trial
Phase 2 clinical trial initiation for IMM-529
Clostridioides difficile infection (CDI)source ↗
●End Of Phase 2 MeetingTravelanFDA Meeting
End of Phase 2 FDA meeting for Travelan (IMM-124E) expected in 1H 2026
Travelers' Diarrheasource ↗
▲Product LaunchPROIBS®Post-Market
ProIBS product launch in Australia expected in 1Q2026
irritable bowel syndromesource ↗
▲IND ClearanceIMM-529IND
FDA approval of IMM-529 IND application
Clostridioides difficile infection (CDI)source ↗
▼Topline ReadoutIMM-124EClinical Data
Uniformed Services University releases topline results for IMM-124E
Gut health during deployment and travel (ETEC)source ↗
▲Product LaunchPROIBS®Post-Market
Launch of PROIBS into Australian market
Irritable Bowel Syndrome (IBS)source ↗
▲Product LaunchPROIBS®Post-Market
Australian launch of ProIBS ahead of schedule before Christmas 2025
IBSsource ↗
▼Topline ReadoutIMM-124EClinical Data
Topline results released for USU study; primary endpoint not met
enterotoxigenic E. coli (ETEC) infectionsource ↗
▲Partnership / LicenseCorporate
New US Department of Defense award to develop two oral therapeutics targeting Campylobacter and Shigella
Campylobacter and Shigellasource ↗
●IND SubmissionIMM-529IND
FDA IND submission for IMM-529
recurrent Clostridioides difficile infectionsource ↗
▲IND ClearanceIMM-529IND
FDA IND clearance for IMM-529
recurrent Clostridioides difficile infectionsource ↗
◆Topline ReadoutTravelanClinical Data
Topline results for Travelan (IMM-124E) clinical trial by Uniformed Services University
Travelers' diarrheasource ↗
◆Topline ReadoutIMM-124EClinical Data
Topline results reported for Uniformed Services University IMM-124E trial
traveler's diarrheasource ↗
▲Partnership / LicenseCorporate
New research agreement with U.S. Department of Defense sub award
◆Topline ReadoutTravelanClinical Data
Topline results from Travelan P2TD study expected end of November 2025
gut health deficienciessource ↗
▲IND ClearanceIMM-529IND
FDA approved IND for IMM-529 Phase 2 trial
Clostridioides difficile infection (CDI)source ↗
◆Topline ReadoutTravelanClinical Data
Topline results from P2TD study expected end of November 2025
Gut health deficienciessource ↗
Past FDA Catalysts and PDUFA Decisions
How IMRN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-31 | IMM-124E (Travelan®) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D37 / 100
Pipeline Score
$4M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.4x
rNPV / MCap
Top 48%
Micro Cap(rank 316 of 658)
Percentile Rank
Immuron Limited faces pipeline headwinds (37/100), with $1.5B risk-adjusted pipeline value, led by Travelan in Diarrhea (Phase 2), across $73B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Travelan Monoclonal antibodyCompletedNCT05933525 | Diarrhea | Phase 2 | COMPLETED | 63 | Dec 30, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every IMRN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| IMM-124E | maintaining gut health during deployment and travel | Phase 2 | 2025-12-10 | the primary endpoint did not reach statistical significanceRead More | Uniformed Services University to Release Topline Data Highlights: Primary Endpoint did not reach statistical significance Investigational product was manufactured by a third party and was not administered in accordance wRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IMRN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IMRN for Q2 2026. | ||||
IMRN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How IMRN ranks across every disease it competes in
Competitive Position is a premium feature
See how IMRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialIMRN News
IMRN▲ +62.2%on this news
Immuron to launch PROIBS® in the United States
Immuron Limited has signed an exclusive distribution agreement with Calmino group AB to launch PROIBS® in the United States. This medical device, aimed at alleviating digestive issues, has shown high user satisfaction in previous studies. Immuron aims to leverage its success in Australia to penetrate the U.S. market, enhancing its portfolio of digestive health products.
Read more →IMRNImmuron Reports FY26 Preliminary Results
Immuron Limited reported strong preliminary results for FY26, with record sales of A$7.7 million, marking a 6% increase from the previous year. The company achieved significant growth in the Australian market and continued expansion in the U.S. and Canada. Key milestones included FDA approval for IMM-529 and a strategic partnership for clinical assets. Looking ahead, Immuron plans to invest further in North America and expand its product portfolio.
Read more →IMRN▼ -6.6%on this news
Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
Immuron Limited's CEO, Steven Lydeamore, will present at the Kalkine Media Webinar on July 20, 2026. The presentation will cover the company's innovative biopharmaceutical products, including Travelan® and IMM-529, aimed at treating infectious diseases. Immuron is recognized for its development of orally delivered targeted polyclonal antibodies.
Read more →IMRN▼ -5%on this newsshared move
Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Immuron Limited reported a 6% increase in FY26 sales, totaling AUD$7.7 million, marking four consecutive quarters of growth. The company's immune supplement, Travelan®, saw notable sales increases driven by enhanced marketing and increased travel. However, some segments experienced a significant decline, and currency fluctuations impacted U.S. sales. The company aims to leverage new packaging to further enhance sales moving forward.
Read more →IMRNImmuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy
Immuron Limited has engaged Pullan Consulting to advance its partnering strategy for IMM-529, a treatment for Clostridioides difficile infection (CDI). The company has received FDA approval for its IND application and is seeking partners to support clinical development and commercialization. The Phase 2 trial aims to evaluate the safety and efficacy of IMM-529 in patients with CDI.
Read more →IMRNMay 2026 Ms Melissa Kostopoulos Senior Adviser, Listings Compliance (Melbourne) ASX Limited Dear Ms Kostopoulos RE: Immuron Limited ( IMC'): Response to Price Query I refer to your letter dated 28 May 2026 regarding IMC'
Immuron Limited (IMC; NASDAQ: IMRN) received a price query letter from ASX's Listings Compliance regarding its recent trading activity. In response, the company affirmed that it is not aware of any undisclosed information that would explain this trading. The response also indicates that the company is compliant with Listing Rules. However, IMC must ensure timely communication with ASX to avoid potential trading suspension or compliance issues.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Emerging Growth Conference Melbourne, Australia, May 8 , 2026 : Immuron Limited (ASX : IMC ; NASDAQ : IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore
Immuron Limited's CEO Steven Lydeamore presented virtually at the Emerging Growth Conference on May 7, 2026. The presentation underscores Immuron's commitment to developing targeted oral therapies for infectious diseases, such as their flagship product Travelan, which aims to prevent travelers' diarrhea. The company's innovative use of polyclonal antibodies derived from bovine colostrum was emphasized, showcasing their platform technology's versatility in addressing gastrointestinal health. This event represents an opportunity for the company to increase its profile and establish new business relationships.
Read more →IMRNImmuron CEO, Steven Lydeamore Emerging Growth Conference
Immuron Limited's CEO, Steven Lydeamore, is set to present at the Emerging Growth Conference on May 7, 2026, highlighting the company's advancements in biopharmaceuticals. Immuron focuses on developing targeted polyclonal antibodies for infectious diseases, with notable products like Travelan for preventing travelers' diarrhea. Moreover, the company is exploring new treatments such as IMM-529 for recurrent Clostridioides difficile infections, showing promise in pre-clinical trials. This conference presentation offers a platform for potential investors and stakeholders to learn about Immuron's progress and future initiatives.
Read more →IMRNEmerging Growth Research Releases Flash Report on Immuron; Maintains Buy-Extended Rating and Raises Price Target to $4.00
Emerging Growth Research has released a Flash Report on Immuron, maintaining a Buy-Extended rating and raising the 12-month price target to $4.00 from $3.90. The report highlights Immuron's double-digit revenue growth, particularly in Australia and the U.S., and strong performance in Canada. The company is advancing its clinical pipeline, including candidates for travelers' diarrhea and C. difficile infections, with FDA clearance for Phase 2 trials.
Read more →IMRN▲ +13.3%on this news
Immuron Double Digit 3Q Sales Growth
Immuron Limited reported a 16% increase in Q3 sales, reaching AUD$1.5 million, driven by effective marketing strategies and expansion into new markets. The company noted significant growth in sales of its product Travelan®, particularly in Canada, though some regions experienced declines year-to-date. The strengthening Australian dollar has impacted U.S. sales, highlighting the challenges of currency fluctuations.
Read more →IMRN▲ +13.3%on this newsshared move
Immuron Double Digit 3Q Sales
Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a 16% increase in global Q3 sales, totaling AUD$1.5 million. The growth is attributed to effective marketing strategies, including increased promotion in existing stores and new listings in Canada. In the U.S., sales remained relatively stable with a 1% increase due to various marketing initiatives. However, the strengthening of the Australian dollar against the U.S. dollar has negatively influenced sales figures. Overall, the company is seeing positive momentum for its Travelan product in key markets.
Read more →IMRNSmall Holding Share Sale Facility
Immuron Limited has announced the establishment of a Small Holding Share Sale Facility for shareholders holding less than $500 worth of ordinary shares. This initiative will enable eligible shareholders to sell their small holdings without incurring any brokerage fees, significantly reducing administrative costs for the company. Shareholders must opt out by a specified date if they do not wish to sell. This program addresses the needs of nearly 1,500 shareholders with small holdings, providing a cost-effective solution for disposing of shares.
Read more →IMRNImmuron CEO, Steven Lydeamore presentation at Coffee Microcaps Conference
Immuron Limited's CEO, Steven Lydeamore, will present virtually at the Coffee Microcaps Conference on March 5, 2026. The company specializes in developing targeted polyclonal antibodies for infectious diseases, including its product Travelan®, which helps prevent travelers' diarrhea. The presentation will highlight Immuron's advancements and product offerings.
Read more →IMRNImmuron Limited Appendix 4D Half-year report 1. Company details Name of entity: Immuron Limited ABN: 80 063 114 045 Reporting period: For the period ended 31 December 2025 Previous period: For the period ended 31 Decembe
Immuron Limited has released its half-year report for the period ending December 31, 2025, indicating a 4.8% increase in revenue to A$4,184,357 and a 22.9% reduction in losses. Although net tangible assets dropped to 3.94 cents per share, the company highlighted record sales of Hyperimmune products and received FDA approval for its IMM-529 IND application. This approval is pivotal for advancing studies on treating Clostridioides difficile infection, a significant health threat.
Read more →IMRN▲ +17.1%on this newsshared move
Immuron Reports HY26 Results and Strategic Reset
Immuron Limited has announced its half-year financial results and a strategic reset, highlighting advancements in its product pipeline, particularly with Travelan and IMM-529. The company is focused on developing targeted polyclonal antibodies for infectious diseases. Positive pre-clinical results for IMM-529 suggest promising potential in treating recurrent Clostridioides difficile infections.
Read more →IMRNMelbourne, Australia, February 17, 2026: Immuron Limited
Immuron Limited has announced that it received A$1,121,885 in R&D Tax Incentive from the Australian Government for the financial year ending June 30, 2025. This funding will act as non-dilutive support, enabling the company to invest further in growth opportunities, particularly within their Hyper-Immune product line. The focus remains on improving profitability while implementing cost reduction strategies to enhance earnings before interest, tax, depreciation, and amortization, excluding R&D expenses. Immuron continues to develop orally delivered targeted polyclonal antibodies for various infectious diseases, particularly for travelers' diarrhea.
Read more →IMRNExtraordinary General Meeting Results
Immuron Limited announced that all resolutions proposed during the 2026 Extraordinary General Meeting were passed by shareholders. The meeting, conducted in accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001, showcases the company's commitment to its growth strategy. Immuron focuses on developing orally delivered targeted polyclonal antibodies derived from engineered bovine colostrum aimed at treating infectious diseases. The company continues to explore opportunities within its proprietary technology framework, which may allow for effective interventions against various pathogens.
Read more →IMRN▼ -6.4%on this newsshared move
Resignation/Appointment of Company Secretary and Chief Financial Officer
Immuron Limited has announced the resignation of Chief Financial Officer and Company Secretary Phillip Hains, effective February 9, 2026. The board expressed gratitude for his contributions since 2013. In his place, Olga Smejkalova has been appointed as Company Secretary, while Aaron Laurita will take on the role of Chief Financial Officer, both effective the same date. The appointments are expected to enhance the company's governance and financial management.
Read more →IMRNCEO, Steven Lydeamore presentation at Emerging Growth Conference
Immuron Limited's CEO, Steven Lydeamore, presented at the Emerging Growth Conference on January 22, 2026, discussing the company's innovations in biopharmaceuticals. Immuron focuses on developing orally delivered polyclonal antibodies, including products like Travelan, an immunotherapy for travelers' diarrhea. The company is also advancing research for therapies targeting recurrent Clostridioides difficile infections and has exclusive distribution agreements for certain medical devices in Australia and New Zealand. The presentation underscores Immuron's potential in addressing significant health issues and advancing their treatment offerings.
Read more →IMRN▼ -7.8%on this newsshared move
Immuron Reports Continued Sales Growth
Immuron Limited has reported continued sales growth for its immune supplement Travelan®, with an 11% increase in Australia and a 17% increase in the U.S. The company successfully launched ProIBS® ahead of schedule and is expanding its presence in Canada. Marketing initiatives and increased consumer awareness have contributed to this growth, despite some challenges such as stock reductions from a key distributor.
Read more →About Immuron Limited
BIOPHARMAWATCH ELITE PLUS
Trade the next IMRN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime